Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV). (22nd July 2020)

• Record Type: Journal Article
• Authors: Bekker, Adrie; Decloedt, Eric H; Slade, Gretchen; Cotton, Mark F; Rabie, Helena; Cressey, Tim R
• Is Part Of: Clinical infectious diseases. Volume 72:Number 11(2021)
• Page Start: 2032
• Page End: 2034
• Publication Date: 2020-07-22
• Subjects: HIV -- neonates -- abacavir -- pharmacokinetics; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa1026
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Abacavir is a potential option for prophylaxis and early treatment of human immunodeficiency virus (HIV), but no data are available in neonates. Ten neonates administered a single abacavir dose of 8 mg/kg before 15 days of life had substantially higher exposures than those reported in infants and children, with no reported adverse events.